These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28670693)

  • 21. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
    Qiao N; Wang L; Wang T; Li H
    Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.
    Sanz-Rodríguez F; Hidalgo A; Teixidó J
    Blood; 2001 Jan; 97(2):346-51. PubMed ID: 11154207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
    Weisberg E; Azab AK; Manley PW; Kung AL; Christie AL; Bronson R; Ghobrial IM; Griffin JD
    Leukemia; 2012 May; 26(5):985-90. PubMed ID: 22182920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment.
    Han Y; Wu C; Wang J; Liu N
    Tumour Biol; 2017 May; 39(5):1010428317701631. PubMed ID: 28468584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
    Udi J; Schüler J; Wider D; Ihorst G; Catusse J; Waldschmidt J; Schnerch D; Follo M; Wäsch R; Engelhardt M
    Br J Haematol; 2013 Apr; 161(1):104-16. PubMed ID: 23384035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR7 Mediates Neural Progenitor Cells Migration to CXCL12 Independent of CXCR4.
    Chen Q; Zhang M; Li Y; Xu D; Wang Y; Song A; Zhu B; Huang Y; Zheng JC
    Stem Cells; 2015 Aug; 33(8):2574-85. PubMed ID: 25833331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
    Beider K; Rosenberg E; Bitner H; Shimoni A; Leiba M; Koren-Michowitz M; Ribakovsky E; Klein S; Olam D; Weiss L; Wald H; Abraham M; Galun E; Peled A; Nagler A
    Clin Cancer Res; 2017 Apr; 23(7):1733-1747. PubMed ID: 27697999
    [No Abstract]   [Full Text] [Related]  

  • 29. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells.
    Tarnowski M; Liu R; Wysoczynski M; Ratajczak J; Kucia M; Ratajczak MZ
    Eur J Haematol; 2010 Dec; 85(6):472-83. PubMed ID: 20887389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
    Wu W; Qian L; Chen X; Ding B
    Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
    Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
    Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis.
    Badr G; Lefevre EA; Mohany M
    PLoS One; 2011; 6(9):e23741. PubMed ID: 21912642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
    Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
    Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.
    Mirandola L; Apicella L; Colombo M; Yu Y; Berta DG; Platonova N; Lazzari E; Lancellotti M; Bulfamante G; Cobos E; Chiriva-Internati M; Chiaramonte R
    Leukemia; 2013 Jul; 27(7):1558-66. PubMed ID: 23354012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
    Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
    Duda DG; Kozin SV; Kirkpatrick ND; Xu L; Fukumura D; Jain RK
    Clin Cancer Res; 2011 Apr; 17(8):2074-80. PubMed ID: 21349998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
    Abdi J; Mutis T; Garssen J; Redegeld FA
    PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
    Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
    Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.